• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Otonomy Inc.

    3/30/23 4:24:29 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    S-8 POS 1 d474350ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 30, 2023

    Registration No. 333-263110

    333-253000

    333-236716

    333-230055

    333-223522

    333-216401

    333-209990

    333-202851

    333-198116

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    Post-Effective Amendment No. 1 to Registration Statement No. 333-263110

    Post-Effective Amendment No. 1 to Registration Statement No. 333-253000

    Post-Effective Amendment No. 1 to Registration Statement No. 333-236716

    Post-Effective Amendment No. 1 to Registration Statement No. 333-230055

    Post-Effective Amendment No. 1 to Registration Statement No. 333-223522

    Post-Effective Amendment No. 1 to Registration Statement No. 333-216401

    Post-Effective Amendment No. 1 to Registration Statement No. 333-209990

    Post-Effective Amendment No. 1 to Registration Statement No. 333-202851

    Post-Effective Amendment No. 1 to Registration Statement No. 333-198116

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OTONOMY, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   26-2590070

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Address Not Applicable1

    (Address of principal executive offices, including zip code)

    2014 Equity Incentive Plan

    2014 Employee Stock Purchase Plan

    (Full title of the plans)

    Otonomy, Inc.

    c/o Corporation Service Company

    251 Little Falls Drive

    Wilmington, New Castle County, Delaware 19808

    (619) 488-6202

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Jennifer Knapp

    Amanda N. Urquiza

    Wilson Sonsini Goodrich & Rosati, P.C.

    650 Page Mill Road

    Palo Alto, California 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act.  ☐

     

     

    1 

    Otonomy, Inc. (the “Company”) terminated its lease agreement for office space. Accordingly, the Company does not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any communication required to be sent to the Company’s principal executive offices may be directed to the Company’s agent for service of process at Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, or to the email address set forth in the Company’s investor relations website.

     

     

     


    EXPLANATORY NOTE

    As contemplated by the Plan of Liquidation and Dissolution of Otonomy, Inc. (the “Company”), the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective on March 28, 2023 and provides for the voluntary liquidation and dissolution of the Company under the General Corporation Law of the State of Delaware (the “Dissolution”). In connection with the Dissolution, all outstanding equity awards granted under or governed by the Company’s equity incentive plans (collectively, the “Plans”), including the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), have been cancelled and each of the Plans has been terminated.

    In accordance with the undertaking in the Registration Statements (as defined below), the Company is hereby filing this Post-Effective Amendment No. 1 to each of the Company’s registration statements on Form S-8 (registration nos. 333-263110, 333-253000, 333-236716, 333-230055, 333-223522, 333-216401, 333-209990, 333-202851 and 333-198116) (collectively, the “Registration Statements”) to terminate the effectiveness of each such Registration Statement and to remove from registration all shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to outstanding equity awards under the Plans, including 14,940,774 shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to outstanding equity awards under the 2014 Plan and 3,669,417 shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to the ESPP.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 30, 2023.

     

    OTONOMY, INC.

    By:   /s/ Paul E. Cayer
      Paul E. Cayer
      President, Secretary and Chief Financial and Business Officer

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements.

    Get the next $OTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/14/23 4:06:58 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/13/23 8:49:22 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/10/23 4:29:37 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Otonomy Announces Change in Stock Exchange Listing

      SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

      12/22/22 7:53:14 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Provides Corporate Update

      SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

      12/19/22 4:53:38 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

      11/10/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Otonomy Inc.

      15-12G - OTONOMY, INC. (0001493566) (Filer)

      4/4/23 3:40:49 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:10 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:09 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Otonomy Appoints Jill Broadfoot to Board of Directors

      SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

      8/19/21 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Financials

    Live finance-specific insights

    See more
    • Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

      7/25/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

      SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

      7/18/22 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

      5/9/22 4:04:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on Otonomy with a new price target

      HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      3/1/21 8:38:28 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

      HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      2/23/21 6:53:19 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Otonomy with a new price target

      Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

      2/22/21 3:01:01 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care